Submitted:
06 May 2024
Posted:
06 May 2024
You are already at the latest version
Abstract
Keywords:
1. Introduction
2. Materials and Methods
2.1. Statistical Analysis
3. Results
4. Discussion
4.1. Limitations and strengths
5. Conclusions
Author Contributions
Funding
Institutional Review Board Statement
Informed Consent Statement
Acknowledgments
Conflicts of Interest
References
- Shields CL, Furuta M, Thangappan A, et al. Metastasis of uveal melanoma millimeter-by-millimeter in 8033 consecutive eyes. Arch Ophthalmol. 2009;127(8):989-998. [CrossRef]
- Singh AD, Raval V, Wrenn J, Zabor EC. Small Choroidal Melanoma: Outcomes After Surveillance Versus Immediate Treatment. Am J Ophthalmol. 2022;241:47-56. [CrossRef]
- Gass JDM. Problems in the differential diagnosis of choroidal nevi and malignant melanomas. Trans Am Acad Ophthalmol Otolaryngol. 1977;83(1):19-48. [CrossRef]
- Melia BM, Diener-West M, Bennett SR, et al. Factors predictive of growth and treatment of small choroidal melanoma: COMS report no. 5. Arch Ophthalmol. 1997;115(12):1537-1544.
- Murray TG, Sobrin L. The case for observational management of suspected small choroidal melanoma. Arch Ophthalmol. 2006;124(9):1342-1344. [CrossRef]
- Mortality in patients with small choroidal melanoma. COMS report no. 4. The Collaborative Ocular Melanoma Study Group. Arch Ophthalmol. 1997;115(7):886-893.
- Vigués-Jorba L, Morwani R, Lorenzo D, et al. Survival in small choroidal melanocytic lesions with risk factors managed by initial observation until detection of tumour growth. Clin Exp Ophthalmol. 2021;49(3):251-259. [CrossRef]
- Shields JA. Treating some small melanocytic choroidal lesions without waiting for growth. Arch Ophthalmol. 2006;124(9):1344-1346. [CrossRef]
- Shields CL, Dalvin LA, Yu MD, et al. Choroidal Nevus Transformation into Melanoma per Millimeter Increment in Thickness using Multimodal Imaging in 2355 Cases: The 2019 wendell l. hughes lecture. Retina. 2019;39(10):1852-1860.
- Damato B. Ocular treatment of choroidal melanoma in relation to the prevention of metastatic death – A personal view. Prog Retin Eye Res. 2018;66:187-199. [CrossRef]
- Folberg R, Rummelt V, Parys-Van Ginderdeuren R, et al. The Prognostic Value of Tumor Blood Vessel Morphology in Primary Uveal Melanoma. Ophthalmology. 1993;100(9):1389-1398. [CrossRef]
- Wang JC, Miller JB. Optical Coherence Tomography Angiography: Review of Current Technical Aspects and Applications in Chorioretinal Disease. Semin Ophthalmol. 2019;34(4):211-217. [CrossRef]
- Naseripour M, Ghasemi Falavarjani K, Mirshahi R, Sedaghat A. Optical coherence tomography angiography (OCTA) applications in ocular oncology. Eye. 2020;34(9):1535-1545. [CrossRef]
- Maloca P, Gyger C, Hasler PW. A pilot study to image the vascular network of small melanocytic choroidal tumors with speckle noise-free 1050-nm swept source optical coherence tomography (OCT choroidal angiography). Graefe’s Arch Clin Exp Ophthalmol. 2016;254(6):1201-1210. [CrossRef]
- Ali ZC, Gray J, Balaskas K. Features of choroidal naevi on swept source optical coherence tomography angiography and structural reverse flow optical coherence tomography. Graefe’s Arch Clin Exp Ophthalmol. 2018;256(7):1319-1323. [CrossRef]
- Cennamo G, Romano MR, Breve MA, et al. Evaluation of choroidal tumors with optical coherence tomography: Enhanced depth imaging and OCT-angiography features. Eye. 2017;31(6):906-915. [CrossRef]
- Ghassemi F, Mirshahi R, Fadakar K. Optical coherence tomography angiography in choroidal melanoma and nevus. Clin Ophthalmol. 2018:12-207. [CrossRef]
- Toledo JJ, Asencio M, García JR, Morales LA, Tomkinson C, Cajigal C. OCT Angiography: Imaging of Choroidal and Retinal Tumors. Ophthalmol Retin. 2018;2(6):613-622. [CrossRef]
- Lee MD, Kaidonis G, Kim AY, Shields RA, Leng T. En Face Optical Coherence Tomography Angiography Imaging Versus Fundus Photography in the Measurement of Choroidal Nevi. Ophthalmic Surg Lasers Imaging Retina. 2017;48(9):741-747. [CrossRef]
- Pellegrini M, Staurenghi G, Preziosa C. Clinical Applications of Optical Coherence Tomography Angiography in Ocular Oncology: Pearls and Pitfalls. Ocul Oncol Pathol. 2022;8(2):79-87. [CrossRef]
- Garcia-Arumi Fuste C, Peralta Iturburu F, Garcia-Arumi J. Is optical coherence tomography angiography helpful in the differential diagnosis of choroidal nevus versus melanoma? Eur J Ophthalmol. 2020;30(4):723-729.
- Gönen B, Hepokur M, Güleser ÜY, Yetik H, Sarıcı AM. Retinal Vascular Patterns and Capillary Plexus Reflectivity of Intraocular Tumors; an Optical Coherence Tomography Angiography Study. Curr Eye Res. 2022;47(10):1424-1435. [CrossRef]
- Greig EC, Laver N V., Mendonca LSM, et al. Swept-Source Optical Coherence Tomography Angiography in Small Choroidal Melanomas and Choroidal Nevi. Retina. 2021;41(6):1182-1192. [CrossRef]
- JD Brierley, MK Gospodarowicz CW. TNM Classification of Malignant Tumours 8th ed. 2017.
- Shields CL, Furuta M, Berman EL, et al. Choroidal nevus transformation into melanoma: Analysis of 2514 consecutive cases. Arch Ophthalmol. 2009;127(8):981-987.
- Zudaire E, Gambardella L, Kurcz C, Vermeren S. A computational tool for quantitative analysis of vascular networks. PLoS One. 2011;6(11):1-12. [CrossRef]
- Schindelin, J., Arganda-Carreras, I., Frise, E., Kaynig, V., Longair, M., Pietzsch, T., Cardona A. Fiji: an open-source platform for biological-image analysis. Nat Methods. 2012;9(7):676-682. [CrossRef]
- Shields CL, Dalvin LA, Ancona-Lezama D, et al. Choroidal nevus imaging features in 3,806 cases and risk factors for transformation into melanoma in 2,355 cases. Retina. December 2018:1. [CrossRef]






| Variable | Total (n=86) | Nevi (n=67) | Melanomas (n=19) |
P value† | RR for growth (95% CI)† |
|---|---|---|---|---|---|
| DEMOGRAPHICS | |||||
| Age at diagnosis, mean (SD) | 61.01 (13.9) | 60.6 (15.1) | 62.4 (9.1) | 0.633* | |
| Sex Female, n (%) Male, n (%) |
49 (57.0) 37 (43.0) |
37(55.2) 30 (44.8) |
12 (63.2) 7 (36.8) |
0.538** |
0.77 (0.3-1.8) |
| Laterality Right eye, n (%) Left eye, n (%) |
46 (53.5) 40 (46.5) |
35 (52.2) 32 (47.8) |
11 (57.9) 8 (42.1) |
0.663** | |
| Visual acuity, median (IQR) | 0.9 (0.5) | 0.9 (0.4) | 0.8 (0.5) | 0.369*** | |
| SMALL MELANOCYTIC LESIONS | |||||
| Thickness (mm), mean (SD) | 1.22 (0.72) | 1.04 (0.67) | 1.88 (0.46) | 0.000*** | |
| Greatest basal diameter (mm), mean (SD) | 5.91 (2.77) | 5.23 (2.55) | 8.34 (2.13) | 0.000* | |
| Distance to the optic nerve (mm), median (IQR) | 2.75 (4.2) | 2.70 (4.6) | 3.00 (2.3) | 0.766*** | |
| Distance to fovea (mm), median (IQR) | 1.20 (3.7) | 1.70 (4.2) | 0.00 (2.8) | 0.213*** | |
| Number of risk factors present at diagnosis, median (IQR) | 4 (3) | 3 (2) | 6 (1.5) | 0.000* | |
| Thickness >2mm, n (%) | 12 (14.0) | 6 (8.96) | 6 (31.6) | 0.021**** | 2.85 (1.3-6.0) |
| Subretinal fluid in optical coherence tomography, n (%) | 45 (52.3) | 32 (47.8) | 13 (68.4) | 0.112** | 1.97 (0.8-4.7) |
| Symptoms, n (%) | 40 (46.5) | 25 (37.3) | 15 (78.9) | 0.001** | 4.3 (1.6-11.9) |
| Orange pigment, n (%) | 33 (38.4) | 18 (26.9) | 15 (78.9) | 0.000** | 6.02 (2.2-16.6) |
| Margin ≤ 3mm from optic nerve, n (%) | 48 (55.8) | 37 (55.2) | 11 (57.9) | 0.836** | 1.09 (0.5-2.4) |
| Ultrasonographic hollowness (Kappa sign), n (%) | 15 (17.4) | 5 (7.46) | 10 (52.6) | 0.000**** | 5.26 (3.6-10.7) |
| Halo, n (%) | 2 (2.3) | 2 (2.99) | 0 (0.0) | 1.000**** | 0.97 (0.9-1.0) |
| Drusen, n (%) | 42 (48.8) | 36 (53.7) | 6 (31.6) | 0.088** | 0.48 (0.2-1.2) |
| CHANGES DURING FOLLOW-UP | |||||
| Lesion growth, n (%) | 19 (22.1) | 0 (0.00) | 19 (100) | ||
| Local recurrence after Brachytherapy treatment, n (%) | 1 (1.16) | 0 (0.0) | 1 (5.3) | 0.221**** | |
| Metastasis, n (%) | 0 (0.00) | 0 (0.0) | 0 (0.0) | ||
| Death, n (%) | 3 (3.5) | 2 (3.0) | 1 (5.3) | 0.532**** | |
| Follow-up (months), median (IQR) | 41.5 (26) | 41 (29) | 44 (20) | 0.337* |
| Variable | Total (n=86) | Nevi (n=67) | Melanomas (n=19) |
P value† | RR for growth (95% CI)† |
|---|---|---|---|---|---|
| Largest vessel diameter (µm), median (IQR) | 56.1 (31.1) | 55.1 (28.0) | 62.8 (47.2) | 0.135*** | |
| Largest vessel diameter ≥100µm, n (%) | 14 (16.3) | 7 (10.4) | 7 (36.8) | 0.012**** | 3 (1.4-6.3) |
| Largest vessel diameter ≥76.3µm, n (%) | 23 (26.7) | 14 (20.9) | 9 (47.4) | 0.025**** | 2.46 (1.2-5.3) |
| Well-defined margins, n (%) | 23 (26.74) | 20 (29.9) | 3 (15.8) | 0.222** | 0.51 (0.2-1.6) |
| Hyper-reflective ring, n (%) | 28 (32.56) | 23 (34.3) | 5 (26.3) | 0.511** | 0.74 (0.3-1.8) |
| Choriocapillaris vascular flow, n (%) | 83 (96.51) | 66 (98.5) | 17 (89.5) | 0.121**** | 0.31 (0.1-0.8) |
| Intra-lesional vascular flow, n (%) | 47 (54.65) | 34 (50.7) | 13 (68.4) | 0.172** | 1.80 (0.8-4.3) |
| Intra-lesional vascularisation, n (%) | 85 (98.84) | 66 (98.5) | 19 (100) | 1.000**** | 1 |
| Fine vascularisation pattern, n (%) | 74 (86.05) | 59 (88.1) | 15 (78.9) | 0.452**** | 0.61 (0.2-1.5) |
| Vessel loops, n (%) | 50 (58.14) | 39 (58.2) | 11 (57.9) | 0.980** | 0.99 (0.4-2.2) |
| Variable | Total (n=86) |
Nevi (n=67) |
Melanomas (n=19) |
P value† |
|---|---|---|---|---|
| Median (IQR) | ||||
| Fractal box count, n | 1.87 (0.04) | 1.88 (0.03) | 1.84 (0.04) | 0.515 |
| Proportion of high flux areas, % | 47.0 (7.2) | 47.0 (7.2) | 47.4 (6.4) | 0.525 |
| Vessel percentage area, % | 51.7 (3.2) | 51.7 (2.5) | 49.9 (4.4) | 0.052 |
| Junction density, junctions/mm2 | 0.0018 (0.001) | 0.0019 (0.001) | 0.0018 (0.002) | 0.336 |
| Mean lacunarity (Λ) | 0.037 (0.02) | 0.037 (0.02) | 0.038 (0.02) | 0.122 |
Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content. |
© 2024 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (http://creativecommons.org/licenses/by/4.0/).